AstraZeneca published nine-month and third-quarter results on October 30. Nine-month revenue rose 7% at constant exchange rates to USD46.881bn and reported operating profit reached USD11.797bn, while 12 Phase III programmes produced positive readouts. Yet operating cash inflow fell to USD10.890bn from USD12.233bn and net debt rose to USD25.833bn. The edition therefore tests whether scientific output is becoming durable cash value rather than relying on adjusted earnings alone.
AstraZeneca researches, develops, manufactures and commercialises prescription medicines across Oncology, BioPharmaceuticals and Rare Disease. Revenue is diversified by medicine and geography, but long-term economics depend on patents, clinical success, reimbursement, launch execution and reinvestment in internal and acquired science.
英文原文 · EN
四个不同日期Analysis: November 9, 2026. Latest report period: nine months ended September 30; results and SEC 6-K: October 30. Quote: London Stock Exchange close November 6. FY2025 Form 20-F filed February 24, 2026.
已保存报价: £139.30 · 2026-11-06. 报价获取日期: 2026-11-09T07:14:07Z. London Stock Exchange:AZN · market quote
财务来源核查及获取日期: 2026-11-09T07:14:07Z.
01
Business model: three therapy engines, one reinvestment loop
For 9M 2026, Oncology generated USD21.889bn, 47% of total revenue, and grew 16% at constant exchange rates. BioPharmaceuticals contributed USD16.731bn and Rare Disease USD7.544bn. The portfolio is therefore broad, but the growth mix is uneven: respiratory and immunology and Rare Disease expanded while CVRM and infectious disease contracted.
The economic moat rests on patents, clinical evidence, regulatory approvals, manufacturing and access rather than a single consumer brand. It must be rebuilt continuously. Internal R&D expense was USD11.439bn in the first nine months, while external licences and acquisitions created a second reinvestment channel outside operating cash flow.
一手来源 ↗02
Latest results: reported growth and the cash-flow gap
Nine-month revenue was USD46.881bn, reported operating profit USD11.797bn and profit for the period USD8.705bn. Reported EPS rose 10% and Core EPS 14% at actual exchange rates. Management retained FY2026 guidance for mid-to-high single-digit revenue growth and low-double-digit Core EPS growth at constant exchange rates; this guidance is not used as the model's forecast.
Operating cash inflow fell USD1.343bn year over year to USD10.890bn. The filing attributes the decline chiefly to working capital, Farxiga loss of exclusivity, higher cash tax and currency effects. The result is a useful warning that earnings and cash can diverge during a patent and launch transition.
一手来源 ↗03
Debt and capital allocation: flexibility with a rising claim
At September 30, cash and current investments were USD8.166bn, gross debt including leases USD34.191bn and company-defined net debt USD25.833bn, up USD2.459bn since year-end. New long-term borrowing of USD4.972bn exceeded USD2.456bn of repayments. Moody's A1 and S&P A+ long-term ratings were unchanged.
AstraZeneca reported USD12.8bn of financial resources, including USD4.9bn of undrawn committed facilities available to April 2031 and no financial covenants. That supports pipeline funding, but it does not make external R&D free: the return on acquired assets and the refinancing of near-term maturities remain part of the equity risk.
一手来源 ↗04
DCF: a conservative post-reinvestment capacity test
The TTM bridge is built only from filed periods: FY2025 less 9M 2025 plus 9M 2026. It produces USD13.232bn of operating cash flow, USD3.463bn of tangible and software capital expenditure, USD0.764bn of share-based payment expense and USD5.276bn of cash spent on acquired intangibles, businesses and contingent consideration. The remaining USD3.729bn is an analytical cash-capacity starting point, not reported free cash flow.
The bear, base and bull cases use different five-year cash growth and equity discount-rate paths. All values are aggregate present values before a complete net-debt, pension, contingent-liability, currency and share-count bridge. A high terminal share is a warning about model duration, not evidence of precision.
一手来源 ↗五年DCF：总体现金流能力
起始期间: 2025-10-01 / 2026-09-30 · trailing twelve months. CFO 13.232 USD 十亿 − 资本支出 3.463 USD 十亿 − SBC 0.764 USD 十亿 − acquired intangibles, businesses and contingent consideration 5.276 USD 十亿 = 3.729 USD 十亿.
全年起始代理值（×1）: 3.729 USD 十亿. USD3.729bn is a calculated TTM analytical starting point, not AstraZeneca's reported free cash flow or guidance. Forecast Y1–Y5 begins after September 30, 2026.
公式：PV = Σ CFₜ/(1+kₑ)ᵗ + CF₅(1+g)/(kₑ−g)/(1+kₑ)⁵。净现金流增长包含持续再投资、股权薪酬和营运资本的影响。永续增长假设扣除这些成本后的净现金具有可持续性。
基准情景 · 分析日期之后的模型年度| 年 | 增长率 | 现金流 | 现值 |
|---|
| Y1 | 8% | 4.027 USD 十亿 | 3.712 USD 十亿 |
|---|
| Y2 | 7% | 4.309 USD 十亿 | 3.661 USD 十亿 |
|---|
| Y3 | 6% | 4.568 USD 十亿 | 3.576 USD 十亿 |
|---|
| Y4 | 5% | 4.796 USD 十亿 | 3.461 USD 十亿 |
|---|
| Y5 | 4% | 4.988 USD 十亿 | 3.317 USD 十亿 |
|---|
情景 · 分析假设，未赋予概率| 情景 | kₑ / g | 五年增长率 | 现金流现值 | 终值占比 |
|---|
| 悲观 | 10% / 1.5% | -5% → 0% → 2% → 2% → 2% | 41.589 USD 十亿 | 67.02% |
|---|
| 基准 | 8.5% / 2.5% | 8% → 7% → 6% → 5% → 4% | 74.396 USD 十亿 | 76.17% |
|---|
| 乐观 | 7.5% / 3% | 12% → 11% → 9% → 7% → 5% | 110.481 USD 十亿 | 81.93% |
|---|
悲观: Patent erosion, slower reimbursement and further external portfolio spending absorb launch growth; a higher required return reflects clinical and capital-allocation risk.
基准: Oncology, respiratory/immunology and rare-disease launches more than offset mature-product decline, while post-reinvestment cash growth fades toward a mature pharmaceutical rate.
乐观: Multiple late-stage assets reach broad labels and commercial scale, working capital recovers and external R&D spending produces stronger cash productivity.
Aggregate levered cash capacity after interest, tax and disclosed productive/external portfolio reinvestment. No per-share target or separate release of cash is asserted; debt, leases, pensions, contingent liabilities, currency and diluted shares require a separate equity bridge.